Breaking News, Collaborations & Alliances

Solid Biosciences, Forge Biologics Enter Development and Manufacturing Pact

To bolster Solid Biosciences’ gene therapy pipeline, including AAV process development, scale up and cGMP manufacturing services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Solid Biosciences, a life sciences company focused on advancing therapies for Duchenne muscular dystrophy, and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), formed a partnership to advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne. SGT-003 is a preclinical candidate that combines a next-generation and rationally designed capsid with Solid’s proprietary nNOS-containing micr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters